BASEL, SWITZERLAND--(Marketwire - November 21, 2008) - Basilea Pharmaceutica Ltd. announces that Zevtera™ (ceftobiprole medocaril), the first-in-class anti-MRSA broad-spectrum cephalosporin, received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of complicated skin and soft tissue infections.
